Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803
- PMID: 21257306
- PMCID: PMC3073413
- DOI: 10.1016/j.ejca.2010.12.015
Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803
Abstract
Background: The ACCENT group previously established disease-free survival (DFS) with 2 or 3 years median follow-up to predict 5 year overall survival (5 year OS) in stage II and III colon cancer. ACCENT further proposed (1) a stronger association between DFS and OS in stage III than II, and (2) 6 or 7 years necessary to demonstrate DFS/OS surrogacy in recent trials. The relationship between end-points in trials with oral fluoropyrimidines, oxaliplatin and irinotecan is unknown.
Methods: Associations between the treatment effect hazard ratios (HRs) on 2 and 3 years DFS, and 5 and 6 years OS were examined in 6 phase III trials not included in prior analyses from 1997 to 2002. Individual data for 12,676 patients were analysed; two trials each tested oxaliplatin, irinotecan and oral treatment versus 5-FU/LV.
Findings: Overall association between 2/3 year DFS and 5/6 year OS HRs was modest to poor (simple R² measures: 0.58-0.76, model-based R²: 0.17-0.49). In stage III patients, the association increased (model-based R² ≥ 0.79). Observed treatment effects on 2 year DFS accurately 5/6 year OS effects overall and in stage III patients.
Interpretation: In recent trials of cytotoxic chemotherapy, 2 or 3 years DFS HRs are highly predictive of 5 and 6 years OS HRs in stage III but not stage II patients. In all patients the DFS/OS association is stronger for 6 year OS, thus at least 6 year follow-up is recommended to assess OS benefit. These data support DFS as the primary end-point for stage III colon cancer trials testing cytotoxic agents.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Figures






Similar articles
-
Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database.J Clin Oncol. 2013 Jul 10;31(20):2600-6. doi: 10.1200/JCO.2013.49.6638. Epub 2013 Jun 3. J Clin Oncol. 2013. PMID: 23733765 Free PMC article.
-
Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.JAMA Netw Open. 2020 Oct 1;3(10):e2020425. doi: 10.1001/jamanetworkopen.2020.20425. JAMA Netw Open. 2020. PMID: 33074326 Free PMC article. Clinical Trial.
-
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.J Clin Oncol. 2015 Dec 10;33(35):4176-87. doi: 10.1200/JCO.2015.63.4238. Epub 2015 Nov 2. J Clin Oncol. 2015. PMID: 26527776 Clinical Trial.
-
Adjuvant therapy of colon cancer.Semin Oncol. 2001 Feb;28(1):30-40. doi: 10.1016/s0093-7754(01)90043-0. Semin Oncol. 2001. PMID: 11254865 Review.
-
The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence.Pharmacoeconomics. 2015 May;33(5):457-66. doi: 10.1007/s40273-015-0257-z. Pharmacoeconomics. 2015. PMID: 25616671 Review.
Cited by
-
Adjuvant Chemotherapy for Stage II Colon Cancer.Cancers (Basel). 2020 Sep 10;12(9):2584. doi: 10.3390/cancers12092584. Cancers (Basel). 2020. PMID: 32927771 Free PMC article. Review.
-
Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database.J Geriatr Oncol. 2016 Nov;7(6):422-429. doi: 10.1016/j.jgo.2016.07.002. Epub 2016 Jul 25. J Geriatr Oncol. 2016. PMID: 27468630 Free PMC article.
-
Making sense of adjuvant chemotherapy in colorectal cancer.J Gastrointest Oncol. 2019 Dec;10(6):1183-1192. doi: 10.21037/jgo.2019.06.03. J Gastrointest Oncol. 2019. PMID: 31949938 Free PMC article. Review.
-
Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database.J Clin Oncol. 2016 Mar 10;34(8):843-53. doi: 10.1200/JCO.2015.63.0558. Epub 2016 Jan 25. J Clin Oncol. 2016. PMID: 26811529 Free PMC article.
-
Deep Convolutional Neural Network-Based Lymph Node Metastasis Prediction for Colon Cancer Using Histopathological Images.Front Oncol. 2021 Jan 13;10:619803. doi: 10.3389/fonc.2020.619803. eCollection 2020. Front Oncol. 2021. PMID: 33520727 Free PMC article.
References
-
- Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352–358. - PubMed
-
- Sargent DJ, Sobrero A, Grothey A, O’Connell MJ, Buyse M, Andre T, Zheng Y, Green E, Labianca R, O’Callaghan C, Seitz JF, Francini G, Haller D, Yothers G, Goldberg R, de Gramont A. Evidence for cure by adjuvant therapy in colon cancer: Observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009 Feb. 2027(6):872–877. - PMC - PubMed
-
- Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005 Dec 1;23(34):8664–70. - PubMed
-
- Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, Buyse M, Labianca R, Seitz JF, O’Callaghan CJ, Francini G, Grothey A, O’Connell M, Catalano PJ, Kerr D, Green E, Wieand HS, Goldberg RM, de Gramont A. End points for colon cancer adjuvant trials: Observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol. 2007 Oct. 1025(29):4569–4574. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources